BillionToOne, Inc. Class A
As of Oct 22, 2026, BillionToOne is in Stage 3, the topping phase, now in week 8 (since Sep 2, 2026). It closed at $105.68, above its 200-day average, which is rising.
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is BLLN early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
BLLN among Diagnostics & Research44th of 44 by relative strength
All 44 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CDNA | Stage 2 · wk 24 | 99 | +27.3% |
| 2 | BDSX | Stage 2 · wk 18 | 98 | −18.3% |
| 3 | ILMN | Stage 2 · wk 24 | 97 | +5.5% |
| 4 | GH | Stage 2 · wk 21 | 97 | −7.6% |
| 5 | NTRA | Stage 2 · wk 20 | 96 | +2.7% |
| 6 | CRL | Stage 2 · wk 16 | 92 | +22.5% |
| 7 | RVTY | Stage 2 · wk 18 | 90 | +10.7% |
| 8 | PSNL | Stage 2 · wk 17 | 90 | −3.2% |
| …44 | BLLN | Stage 3 · wk 8 | — | −7.6% |
BillionToOne: quick answers
What stage is BillionToOne in?
As of Oct 22, 2026, BillionToOne (BLLN) is in Stage 3, the topping phase. It entered Stage 3 on Sep 2, 2026 and is in week 8. What the four stages mean
Is BillionToOne in an uptrend?
Its uptrend has stalled. BillionToOne is in Stage 3, the topping phase that follows an advance. It trades 10.3% above its 200-day average, which is rising.
How has BillionToOne performed over the past year?
As of Oct 22, 2026, BillionToOne is up 18.4% so far in 2026.
Which sector and industry is BillionToOne in?
BillionToOne is in the Diagnostics & Research industry, part of the Health Care sector.
About this companyHealth Care· Diagnostics & Research
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.